LLY director logs 12.259 shares via fee deferral at $808.96
Rhea-AI Filing Summary
Eli Lilly (LLY) director Mary Lynne Hedley reported an acquisition of 12.259 shares of common stock on 10/20/2025 at $808.96 per share. The filing states the shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common stock following her separation from service.
After the transaction, beneficial ownership stood at 2,015.828 shares held directly and 98 shares held indirectly by trust.
Positive
- None.
Negative
- None.
Insights
Routine director fee deferral reported; minimal market impact.
The report shows a small acquisition tied to director compensation mechanics, not an open-market purchase. The shares were deferred as stock units under the Directors' Deferral Plan and are slated for settlement in common stock after service ends.
Because this is compensation-related and modest in size, it typically does not change the investment view on Eli Lilly. The filing also lists updated beneficial ownership levels following the transaction.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 12.259 | $808.96 | $10K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. The reporting person disclaims beneficial ownership of the reported securities except to the extent of the reporting person's pecuniary interest therein, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.